NO321390B1 - Anvendelse av en forbindelse for fremstilling av et medikament for behandling av neuropatisk smerte - Google Patents

Anvendelse av en forbindelse for fremstilling av et medikament for behandling av neuropatisk smerte Download PDF

Info

Publication number: NO321390B1
Authority: NO; Norway
Prior art keywords: alkyl; formula; rog; hydrogen; compound
Prior art date: 1996-10-08

Application number

NO19991621A

Other languages

English (en)

Norwegian (no)

Other versions

NO991621D0 (no

NO991621L (no

Inventor

Richard P Shank

Kenneth Wild

Original Assignee

Ortho Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-08

Filing date

1999-04-06

Publication date

2006-05-08

1999-04-06 Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp

1999-04-06 Publication of NO991621D0 publication Critical patent/NO991621D0/no

1999-05-25 Publication of NO991621L publication Critical patent/NO991621L/no

2006-05-08 Publication of NO321390B1 publication Critical patent/NO321390B1/no

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 20
208000004296 neuralgia Diseases 0.000 title claims abstract description 12
208000021722 neuropathic pain Diseases 0.000 title claims abstract description 12
239000003814 drug Substances 0.000 title claims description 4
238000004519 manufacturing process Methods 0.000 title 1
125000000217 alkyl group Chemical group 0.000 claims abstract description 16
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims abstract description 12
229960004394 topiramate Drugs 0.000 claims abstract description 12
239000001257 hydrogen Substances 0.000 claims abstract description 11
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 7
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 6
239000001301 oxygen Substances 0.000 claims abstract description 6
229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
-1 methylenedioxy moiety Chemical group 0.000 claims abstract description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 4
150000002431 hydrogen Chemical class 0.000 claims abstract description 4
238000002360 preparation method Methods 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 4
150000001721 carbon Chemical group 0.000 claims description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
238000000034 method Methods 0.000 abstract description 8
125000002009 alkene group Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
210000002683 foot Anatomy 0.000 description 8
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000002904 solvent Substances 0.000 description 6
206010010904 Convulsion Diseases 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
241000700159 Rattus Species 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
238000010171 animal model Methods 0.000 description 4
206010015037 epilepsy Diseases 0.000 description 4
208000004454 Hyperalgesia Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000001961 anticonvulsive agent Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
WJXREUZUPGMAII-UHFFFAOYSA-N sulfurazidic acid Chemical compound OS(=O)(=O)N=[N+]=[N-] WJXREUZUPGMAII-UHFFFAOYSA-N 0.000 description 2
FZUJWWOKDIGOKH-UHFFFAOYSA-N sulfuric acid hydrochloride Chemical compound Cl.OS(O)(=O)=O FZUJWWOKDIGOKH-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229960003107 tramadol hydrochloride Drugs 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
208000033001 Complex partial seizures Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000037158 Partial Epilepsies Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010040703 Simple partial seizures Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
206010053552 allodynia Diseases 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
230000003574 anti-allodynic effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
YUMNNMSNSLHINV-UHFFFAOYSA-N chloro sulfamate Chemical compound NS(=O)(=O)OCl YUMNNMSNSLHINV-UHFFFAOYSA-N 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004705 lumbosacral region Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229910000510 noble metal Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960005235 piperonyl butoxide Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000008213 purified water Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000001032 spinal nerve Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
235000013759 synthetic iron oxide Nutrition 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

NO19991621A 1996-10-08 1999-04-06 Anvendelse av en forbindelse for fremstilling av et medikament for behandling av neuropatisk smerte NO321390B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2768796P	1996-10-08	1996-10-08
PCT/US1997/012350 WO1998015270A1 (en)	1996-10-08	1997-07-16	Anticonvulsant derivatives useful in treating neuropathic pain

Publications (3)

Publication Number	Publication Date
NO991621D0 NO991621D0 (no)	1999-04-06
NO991621L NO991621L (no)	1999-05-25
NO321390B1 true NO321390B1 (no)	2006-05-08

Family

ID=21839205

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19991621A NO321390B1 (no)	1996-10-08	1999-04-06	Anvendelse av en forbindelse for fremstilling av et medikament for behandling av neuropatisk smerte

Country Status (23)

Country	Link
EP (1)	EP0932400B1 (de)
JP (1)	JP4097294B2 (de)
KR (1)	KR100496934B1 (de)
CN (1)	CN1105559C (de)
AP (1)	AP1513A (de)
AT (1)	ATE226071T1 (de)
AU (1)	AU725570B2 (de)
BR (1)	BR9712503A (de)
CA (1)	CA2267945C (de)
CZ (1)	CZ296525B6 (de)
DE (1)	DE69716453T2 (de)
DK (1)	DK0932400T3 (de)
ES (1)	ES2187795T3 (de)
HU (1)	HU225031B1 (de)
IL (1)	IL129276A (de)
NO (1)	NO321390B1 (de)
NZ (1)	NZ334981A (de)
PT (1)	PT932400E (de)
RU (1)	RU2175868C2 (de)
SI (1)	SI0932400T1 (de)
SK (1)	SK284271B6 (de)
UA (1)	UA48256C2 (de)
WO (1)	WO1998015270A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1182845C (zh) *	1999-01-19	2005-01-05	奥索-麦克尼尔药品公司	用于治疗集束性头痛的抗惊厥剂衍生物
AU3582600A (en) *	1999-01-21	2000-08-07	Ortho-Mcneil Pharmaceutical, Inc.	Anticonvulsant derivatives useful in treating transformed migraine
AU2002227052A1 (en)	2000-11-30	2002-06-11	University Of Florida	Treatments for neurogenetic disorders, impulse control disorders, and wound healing
MXPA03007721A (es) *	2001-02-27	2004-11-12	Johnson & Johnson	Compuesto de carbamato para su uso en el tratamiento del dolor.
FR2852244B1 (fr) *	2003-03-13	2007-09-07	Pf Medicament	Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
MY147767A (en)	2004-06-16	2013-01-31	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US8691867B2 (en)	2005-12-19	2014-04-08	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en)	2005-12-19	2013-07-30	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en)	2005-12-19	2015-01-20	Janssen Pharmaceutica Nv	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) *	2005-12-19	2014-05-06	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AU2007253814A1 (en)	2006-05-19	2007-11-29	Janssen Pharmaceutica N.V.	Co-therapy for the treatment of epilepsy
JP5912269B2 (ja)	2011-03-11	2016-04-27	ローランド株式会社	電子楽器
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4513006A (en) *	1983-09-26	1985-04-23	Mcneil Lab., Inc.	Anticonvulsant sulfamate derivatives
US5998380A (en) *	1995-10-13	1999-12-07	New England Medical Center Hospitals, Inc.	Treatment of migraine

1997
- 1997-07-16 AT AT97932615T patent/ATE226071T1/de not_active IP Right Cessation
- 1997-07-16 EP EP97932615A patent/EP0932400B1/de not_active Expired - Lifetime
- 1997-07-16 NZ NZ334981A patent/NZ334981A/xx unknown
- 1997-07-16 KR KR10-1999-7002879A patent/KR100496934B1/ko not_active Expired - Fee Related
- 1997-07-16 UA UA99041953A patent/UA48256C2/uk unknown
- 1997-07-16 SI SI9730316T patent/SI0932400T1/xx unknown
- 1997-07-16 IL IL12927697A patent/IL129276A/xx not_active IP Right Cessation
- 1997-07-16 CZ CZ0115799A patent/CZ296525B6/cs not_active IP Right Cessation
- 1997-07-16 ES ES97932615T patent/ES2187795T3/es not_active Expired - Lifetime
- 1997-07-16 CN CN97198456A patent/CN1105559C/zh not_active Expired - Fee Related
- 1997-07-16 JP JP51749098A patent/JP4097294B2/ja not_active Expired - Fee Related
- 1997-07-16 DE DE69716453T patent/DE69716453T2/de not_active Expired - Fee Related
- 1997-07-16 PT PT97932615T patent/PT932400E/pt unknown
- 1997-07-16 AU AU36022/97A patent/AU725570B2/en not_active Ceased
- 1997-07-16 AP APAP/P/1999/001508A patent/AP1513A/en active
- 1997-07-16 DK DK97932615T patent/DK0932400T3/da active
- 1997-07-16 WO PCT/US1997/012350 patent/WO1998015270A1/en not_active Ceased
- 1997-07-16 SK SK454-99A patent/SK284271B6/sk unknown
- 1997-07-16 HU HU9904294A patent/HU225031B1/hu not_active IP Right Cessation
- 1997-07-16 RU RU99107566/14A patent/RU2175868C2/ru not_active IP Right Cessation
- 1997-07-16 BR BR9712503-2A patent/BR9712503A/pt not_active Application Discontinuation
- 1997-07-16 CA CA002267945A patent/CA2267945C/en not_active Expired - Fee Related
1999
- 1999-04-06 NO NO19991621A patent/NO321390B1/no unknown

Also Published As

Publication number	Publication date
IL129276A (en)	2003-04-10
AP1513A (en)	2005-12-12
UA48256C2 (uk)	2002-08-15
EP0932400A1 (de)	1999-08-04
SK284271B6 (sk)	2004-12-01
SK45499A3 (en)	2000-08-14
RU2175868C2 (ru)	2001-11-20
WO1998015270A1 (en)	1998-04-16
EP0932400B1 (de)	2002-10-16
AU725570B2 (en)	2000-10-12
JP2001501643A (ja)	2001-02-06
ES2187795T3 (es)	2003-06-16
KR20000048871A (ko)	2000-07-25
JP4097294B2 (ja)	2008-06-11
DE69716453D1 (de)	2002-11-21
NO991621D0 (no)	1999-04-06
HU225031B1 (en)	2006-05-29
KR100496934B1 (ko)	2005-06-23
CA2267945A1 (en)	1998-04-16
HUP9904294A3 (en)	2001-08-28
BR9712503A (pt)	1999-10-19
NO991621L (no)	1999-05-25
CN1232393A (zh)	1999-10-20
NZ334981A (en)	2000-08-25
AP9901508A0 (en)	1999-06-30
SI0932400T1 (en)	2002-12-31
PT932400E (pt)	2003-03-31
CZ296525B6 (cs)	2006-04-12
DK0932400T3 (da)	2003-02-10
CN1105559C (zh)	2003-04-16
HUP9904294A2 (hu)	2001-04-28
CZ115799A3 (cs)	1999-09-15
AU3602297A (en)	1998-05-05
DE69716453T2 (de)	2003-02-27
ATE226071T1 (de)	2002-11-15
CA2267945C (en)	2005-05-17
IL129276A0 (en)	2000-02-17

Publication	Publication Date	Title
US5935933A (en)	1999-08-10	Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en)	1998-06-02	Anticonvulsant derivatives useful in treating neuropathic pain
US6620819B2 (en)	2003-09-16	Anticonvulsant derivatives useful in treating psychosis
RU2214241C2 (ru)	2003-10-20	Способ лечения ожирения и способ индуцирования потери веса у млекопитающих
AU775849B2 (en)	2004-08-19	Anticonvulsant derivatives useful in lowering blood pressure
US6191163B1 (en)	2001-02-20	Anticonvulsant derivatives useful in lowering lipids
SK180498A3 (en)	2000-03-13	Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
AU4047800A (en)	2000-11-14	Anticonvulsant derivatives useful in reducing blood glucose levels
EP0932400B1 (de)	2002-10-16	Antikonvulsive derivate zur behandlung von neuropathischem schmerz
US20020052325A1 (en)	2002-05-02	Anticonvulsant derivatives useful in maintaining weight loss
AU764703B2 (en)	2003-08-28	Use of anticonvulsant derivatives for treating bulimia nervosa
EP0964681B1 (de)	2001-08-16	Antikonvulsive derivate zur behandlung von psoriasis
MXPA99003258A (en)	2000-09-04	Anticonvulsant derivatives useful in treating neuropathic pain
AU4685300A (en)	2000-11-17	Anticonvulsant derivatives useful in treating cocaine dependency
CZ295096B6 (cs)	2005-05-18	Léčivo pro léčbu idiopatického třesu nebo aleviaci třesu
KR100498204B1 (ko)	2005-09-15	건선치료에유용한항경련성유도체